Shaoxing Ruoxi Biotechnology

Shaoxing Ruoxi Biotechnology is a clinical-stage biopharmaceutical company based in Shaoxing, China, specializing in the development of innovative peptide therapeutics for metabolic disorders. The company's primary focus is on multi-target agonists that address obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). Its lead candidate, RX-001, is a tri-agonist targeting the GLP-1, GIP, and glucagon receptors, designed to provide superior weight loss and metabolic benefits. Ruoxi Biotech leverages a proprietary technology platform for peptide modification and optimization to improve the efficacy and safety profiles of its drug candidates. The company is backed by prominent venture capital investors and aims to become a leader in the rapidly evolving metabolic health landscape.